文献速递乳腺癌

接受曲妥珠单抗的晚期HER2阳性乳腺癌患者是否均需 upfront 化疗?随机III期试验SAKK 22/99

Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99.
PubMed 文献 · Ann Oncol · 2017-01-01

该随机III期试验入组175例既往未接受抗HER2治疗的晚期HER2阳性乳腺癌患者,比较单用曲妥珠单抗进展后再联合化疗(A组)与 upfront 曲妥珠单抗联合化疗(B组)。主要终点联合化疗后至进展时间(Combination-TTP)两组无显著差异(HR 0.7,95%CI 0.5-1.1,P=0.1)。作者认为序贯策略未显示优效性,但结果提示可推迟化疗及其毒性,尤其对惰性、无内脏病变患者。

要点

  • A组与B组Combination-TTP分别为12.2个月与10.3个月,无显著差异(HR 0.7,95%CI 0.5-1.1,P=0.1)。
  • 总生存两组无显著差异(HR 0.9,95%CI 0.6-1.5,P=0.55)。
  • 无内脏病变患者A组Combination-TTP为21.8个月,B组为10.1个月(非计划分析HR 2.1,95%CI 1.1-4.2,P=0.03)。

核心结论

  • 接受序贯曲妥珠单抗-化疗或 upfront 联合治疗的患者结局相似,未能证明序贯策略的优效性。
  • 结果提示可推迟化疗及其毒性,尤其对惰性、无内脏病变患者,但需更大规模非劣效确证研究。

研究设计与样本

  • 随机III期优效性试验SAKK 22/99,入组175例可测量/可评估的晚期HER2阳性乳腺癌患者,既往未接受抗HER2治疗。
  • 患者随机分配至A组(单用曲妥珠单抗,疾病进展后联合化疗)或B组( upfront 曲妥珠单抗联合化疗)。
  • 化疗在应答患者中≥6周期后可停止,曲妥珠单抗持续至进展;主要终点为联合化疗后至进展时间(Combination-TTP)。

主要发现

  • Combination-TTP在A组为12.2个月,B组为10.3个月,无显著差异(HR 0.7,95%CI 0.5-1.1,P=0.1)。
  • 总生存两组无显著差异(HR 0.9,95%CI 0.6-1.5,P=0.55)。
  • A组引入化疗前中位TTP为3.7个月(95%CI 2.3-5.4),2年时6%患者仍单用曲妥珠单抗。
  • 无内脏病变患者A组Combination-TTP为21.8个月,B组为10.1个月(非计划分析HR 2.1,95%CI 1.1-4.2,P=0.03);有内脏病变患者无差异。
  • 毒性为化疗相关。

关键数值与推荐

  • 主要终点Combination-TTP:A组12.2个月 vs B组10.3个月,HR 0.7(95%CI 0.5-1.1),P=0.1。
  • 总生存:HR 0.9(95%CI 0.6-1.5),P=0.55。
  • 无内脏病变亚组Combination-TTP:A组21.8个月 vs B组10.1个月,非计划分析HR 2.1(95%CI 1.1-4.2),P=0.03。

临床怎么用

  • 原文结论提示可推迟化疗及其毒性,尤其对惰性、无内脏病变患者,但序贯策略未证明优效。
  • 作者指出需更大规模非劣效确证研究,降阶梯策略可在个体患者中讨论。

局限性

  • 原文指出需更大规模非劣效确证研究。
  • 无内脏病变亚组分析为非计划分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: HER2-targeted therapy plus chemotherapy is standard treatment in advanced HER2+ breast cancer. Trastuzumab alone followed by addition of chemotherapy at disease progression versus upfront combination therapy has not been elucidated. PATIENTS AND METHODS: One-hundred seventy-five patients with measurable/evaluable HER2+ advanced disease without previous HER2-directed therapy were randomized to trastuzumab alone followed, at disease progression, by the combination with chemotherapy (Arm A) or upfront trastuzumab plus chemotherapy (Arm B). Chemotherapy could be stopped after ≥6 cycles in responding patients, trastuzumab was continued until progression. The primary endpoint of this superiority trial was time to progression (TTP) on combined trastuzumab-chemotherapy (Combination-TTP) in both arms. Secondary endpoints included response rate, TTP, overall survival, quality of life and toxicity. RESULTS: Combination-TTP was longer than expected in both arms, 12.2 months in Arm A and 10.3 months in Arm B and not significantly different (hazard ratio [HR] 0.7; 95% CI 0.5-1.1; P =0.1). Overall survival was also not significantly different (HR 0.9; 95% CI 0.6-1.5; P = 0.55). In Arm A, the median TTP before introduction of chemotherapy was 3.7 months (95% CI 2.3-5.4), yet at 2 years 6% of patients were still on trastuzumab alone. Patients without visceral disease had a Combination-TTP of 21.8 months in arm A, compared with 10.1 months in arm B (unplanned analysis HR 2.1, 95% CI 1.1-4.2, P = 0.03). Patients with visceral disease showed no difference. Toxicity was chemotherapy-related. CONCLUSION: The outcome of patients receiving sequential trastuzumab-chemotherapy or upfront combination was similar. We failed to demonstrate superiority of the sequential approach. These results nevertheless suggest chemotherapy and its toxicity can be deferred, especially in patients with indolent, non-visceral disease. Despite a larger non-inferiority confirmatory study would be needed, these findings represent an additional proof of concept that de-escalation strategies can be discussed in individual patients.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Pagani O, Klingbiel D, Ruhstaller T, et al. Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99. Ann Oncol. 2017. PMID: 27998961. doi:10.1093/annonc/mdw622

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。